Home » Stocks » ENZN

Enzon Pharmaceuticals, Inc. (ENZN)

Stock Price: $0.5555 USD -0.0245 (-4.22%)
Updated May 13, 2021 3:59 PM EDT - Market closed
Market Cap 41.23M
Revenue (ttm) 431,000
Net Income (ttm) -2.02M
Shares Out 74.22M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend $0.12
Dividend Yield 21.60%
Trading Day May 13
Last Price $0.5555
Previous Close $0.5800
Change ($) -0.0245
Change (%) -4.22%
Day's Open 0.5600
Day's Range 0.4775 - 0.5880
Day's Volume 218,572
52-Week Range 0.0800 - 0.8500

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Compa...

4 months ago - GlobeNewsWire

Looking to Next Step – Acquisition Opportunities Looking to Next Step – Acquisition Opportunities

6 months ago - GlobeNewsWire

CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previously...

7 months ago - GlobeNewsWire

CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual Meeting”)...

8 months ago - GlobeNewsWire

CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights off...

8 months ago - GlobeNewsWire

CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits pre...

8 months ago - GlobeNewsWire

ENZN trades at all time highs, adjusted for dividends, and double the "base case" of the liquidation value.

Other stocks mentioned: SESN
1 year ago - Seeking Alpha

Trading for less than its liquid book value.

1 year ago - Seeking Alpha

About ENZN

Enzon Pharmaceuticals, Inc., together with its subsidiaries, licenses drug products. Its marketed drug products include PegIntron and Sylatron. The company was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Industry
Biotechnology
IPO Date
Feb 15, 1984
CEO
Andrew Rackear
Country
United States
Stock Exchange
OTCMKTS
Ticker Symbol
ENZN
Full Company Profile

Financial Performance

In 2020, ENZN's revenue was $52,000, a decrease of -74.88% compared to the previous year's $207,000. Losses were -$1.31 million, 33.9% more than in 2019.

Financial Statements